BioBanking - The Holy Grail of novel drug and diagnostic developments?

10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality within the field of modern Life Science, that is expected to be important in the proactive awareness of patient health status. Biobanks are also expected to promote the developments of targeted treatments with personalized indicator assays, for effective use of Personalized Medicine treatments in the near future. © 2011 Marko-Varga; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Marko-Varga, G. (2011, May 13). BioBanking - The Holy Grail of novel drug and diagnostic developments? Journal of Clinical Bioinformatics. BioMed Central Ltd. https://doi.org/10.1186/2043-9113-1-14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free